PV is most common in hot and humid climates, where prevalence may be as high as 50%.[7]Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33.
http://www.ncbi.nlm.nih.gov/pubmed/11952286?tool=bestpractice.com
It is also common in temperate climates, especially during the summer months, accounting for 3% of patients seen by dermatologists.[1]Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82.
http://www.ncbi.nlm.nih.gov/pubmed/15451228?tool=bestpractice.com
In 2023, an analysis of a US online health record database found a prevalence rate of 0.67%.[8]Moseley I, Ragi SD, Ouellette S, et al. Tinea versicolour in underrepresented groups: an All of Us database analysis. Skin Health Dis. 2022 Jul 21;3(1):e152.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892469
http://www.ncbi.nlm.nih.gov/pubmed/36751318?tool=bestpractice.com
PV is most often seen in teenagers and young adults.[7]Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33.
http://www.ncbi.nlm.nih.gov/pubmed/11952286?tool=bestpractice.com
It is unusual for young children and older adults to have PV due to reduced sebum production in these age groups.[7]Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33.
http://www.ncbi.nlm.nih.gov/pubmed/11952286?tool=bestpractice.com
However, childhood cases are seen in tropical regions, and one case in a premature 2-week-old infant has been reported, possibly due to hot and humid conditions in an incubator.[9]Odland GF, Kraning KK. Prevalence, morbidity, and cost of dermatological diseases (editorial). J Invest Dermatol. 1979;73(5):395-401.
http://www.jidonline.org/article/S0022-202X(15)45642-8/pdf
http://www.ncbi.nlm.nih.gov/pubmed/501137?tool=bestpractice.com
Cases in older adults occur in the setting of heat and sweating during hospital admission and in the setting of immunocompromise.[10]Wyre HW Jr, Johnson WT. Neonatal pityriasis versicolor. Arch Dermatol. 1981 Nov;117(11):752-3. Cases of iatrogenic immunocompromise-induced pityriasis versicolor secondary to the use of tumour necrosis factor (TNF)-alpha inhibitors have been described.[11]Balestri R, Rech G, Piraccini BM, et al. Pityriasis versicolor during anti-TNF-α monoclonal antibody therapy: therapeutic considerations. Mycoses. 2012 Sep;55(5):444-6.
http://www.ncbi.nlm.nih.gov/pubmed/22283428?tool=bestpractice.com
Infection rates in men and women vary between studies but overall are similar.[1]Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82.
http://www.ncbi.nlm.nih.gov/pubmed/15451228?tool=bestpractice.com